Loading organizations...
§ Private Profile · Galway, Ireland
Medtech company developing a wearable device for pelvic floor strengthening and urinary incontinence.
INNOVO by Atlantic Therapeutics develops a non-invasive wearable device for treating urinary incontinence and pelvic floor weakness in men and women, based in Galway, Ireland. The shorts-based technology utilizes neuromuscular electrical stimulation, delivering 180 targeted contractions per session to strengthen pelvic floor muscles and address the root cause of bladder issues. The company raised nearly €100 million in funding by October 2022, with notable contributions including a €2 million investment from the Western Development Commission in 2021. Lead investors included Seroba Life Sciences, Earlybird, Atlantic Bridge, and the Borski Fund, prior to its acquisition by US medtech firm Caldera Medical. The organization was incorporated in 2017 as a spin-out from BMR Research to commercialize the technology, which was originally developed by Ruth Maher.
INNOVO by Atlantic Therapeutics has raised $70.8M across 4 funding rounds.
INNOVO by Atlantic Therapeutics has raised $70.8M in total across 4 funding rounds.
INNOVO by Atlantic Therapeutics has raised $70.8M across 4 funding rounds. Most recently, it raised $20.4M Other Equity in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 20, 2022 | $20.4M Venture Round | — | — | Announced |
| Feb 16, 2021 | $2.4M Venture Round | Gillian Buckley | Andera Partners, Atlantic Bridge, Earlybird, LSP, Seroba Life Sciences | Announced |
| Jan 1, 2019 | $32M Series B | Anne Portwich | Atlantic Bridge, Borski Fund, Earlybird Venture Capital, Seroba Life Sciences, Andera Partners | Announced |
| Feb 1, 2017 | $16M Series A | Earlybird Venture Capital, Seroba Life Sciences | — | Announced |
INNOVO by Atlantic Therapeutics has raised $70.8M in total across 4 funding rounds.
INNOVO by Atlantic Therapeutics's investors include Gillian Buckley, Andera Partners, Atlantic Bridge, Earlybird, LSP, Seroba Life Sciences, Anne Portwich, Borski Fund, Earlybird Venture Capital.
INNOVO by Atlantic Therapeutics is a medical device developed by Atlantic Therapeutics, a medtech company specializing in non-invasive pelvic floor strengthening solutions for women's health, particularly stress urinary incontinence (SUI).[1][2][3] The core product, INNOVO shorts, deliver neuromuscular electrical stimulation (NMES) via wearable technology, targeting women worldwide who suffer from SUI—a condition affecting 1 in 3 women—by strengthening pelvic floor muscles in 30-minute home sessions, with clinical trials showing 87% of users dry or nearly dry after 12 weeks.[1][4] Atlantic Therapeutics raised $104M before its acquisition by Caldera Medical in September 2023, which expanded INNOVO's global reach while maintaining its Irish innovation hub.[1][3]
The company serves healthcare providers and direct-to-consumer patients, solving the unmet need for non-invasive SUI treatment amid growing demand for femtech solutions, backed by FDA clearance in 2018 as the first transcutaneous electrical stimulator for this use.[1][4][5] Post-acquisition, INNOVO integrates into Caldera Medical's women's health portfolio, driving growth in a market dominated by players like Johnson & Johnson.[2][3]
Atlantic Therapeutics spun out in 2017 from Bio-Medical Research (BMR) in Galway, Ireland, to commercialize INNOVO technology originally developed as the Vital Compact device, which had gained regulatory approval and traction in Europe.[1][2] The idea emerged from BMR's innovation in NMES for pelvic floor rehabilitation, leveraging a strong patent portfolio and freedom-to-operate analyses to attract investors for U.S. expansion.[2] A pivotal moment came in November 2018 with FDA De Novo clearance, making INNOVO the first non-invasive, wearable stimulator for SUI, supported by trials on over 600 subjects.[1][2][4][5]
Early funding milestones included Series A and B rounds, with investors like Seroba Life Sciences citing the large unmet need, non-invasive design, and IP strength; by 2021, it secured additional backers for femtech growth.[2][6] Leadership, including CEO Susan Trent, emphasized clinical robustness, leading to the 2023 acquisition by Caldera Medical, which preserved the Galway team and accelerated worldwide scaling.[3]
Atlantic Therapeutics rides the femtech wave, addressing a $10B+ SUI market with non-invasive alternatives to surgical interventions from giants like Boston Scientific.[2] Timing aligns with rising awareness of women's pelvic health post-pregnancy/childbirth, amplified by remote health tech post-COVID and FDA's support for digital therapeutics.[1][4] Market forces favor INNOVO: aging populations, stigma reduction around incontinence, and investor interest in evidence-based medtech, as seen in its $104M funding and acquisition.[1][3][6]
It influences the ecosystem by pioneering NMES wearables, inspiring connected health devices for pelvic/sexual dysfunctions, and validating spin-outs from research hubs like Galway—boosting Ireland's medtech scene while integrating into Caldera’s prolapse/fibroid portfolio for holistic women's care.[2][3]
Under Caldera Medical, INNOVO is poised for explosive global expansion, targeting U.S./Asia growth with its clinical edge and OTC appeal amid femtech's projected doubling by 2030. Trends like AI-enhanced apps, expanded indications (e.g., sexual health), and telehealth partnerships will propel it, potentially capturing first-mover share in non-invasive SUI. Its evolution from Irish spin-out to acquired leader underscores medtech's power to transform daily burdens for millions of women into leak-free lives.[1][2][3]